Ascentage Pharma’s Novel Cancer Drug Approved in China

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years. On July 10, Ascentage Pharma announced that China’s National Medical Products Administration/NMPA approved its novel Bcl-2 selective inhibitor, called lisaftoclax (APG-2575).

It treats adult patients with chronic lymphocytic leukemia/CLL and small lymphocytic lymphoma/SLL, particularly those who have previously received at least one systemic therapy, which includes Bruton’s tyrosine kinase (BTK) inhibitors. Lisaftoclax is the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL in China, and the second Bcl-2 inhibitor approved globally.

Ascentage Pharma's Novel Cancer Drug Approved in China

A scientist in a lab conducting research on cell-based therapeutics and biotechnology.

Lisaftoclax is an orally administered small-molecule drug designed to treat malignancies by selectively blocking the antiapoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. Clinical trials have demonstrated its therapeutic potential in various hematologic malignancies and solid tumors, particularly CLL/SLL, both as a monotherapy and in combinations.

Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical-stage biotechnology company that develops therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China.

While we acknowledge the potential of AAPG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AAPG and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.